Explore

Rapid Read Rapid Read
NHS Faces Challenges in Patient Pathway Activation for Innovative Treatments

NHS Faces Challenges in Patient Pathway Activation for Innovative Treatments

The NHS is encountering challenges in transitioning from the approval of innovative medical treatments to their real-world adoption. According to experts, the gap between approval and actual patient access is significant, with many treatments stalling due to system complexities. Arlene Neville from IQVIA highlights that organizations often assume clinical efficacy will naturally lead to adoption, but they face a complex system involving multiple sectors. The process of patient pathway activation requires understanding and redesigning these pathways to ensure system readiness for new treatments. This involves addressing bottlenecks, decision-making ownership, and operational constraints.
Rapid Read Rapid Read
Pharmacy Education Faces Challenges in Preparing Pharmacists for Cognitive Demands

Pharmacy Education Faces Challenges in Preparing Pharmacists for Cognitive Demands

Pharmacy education in the UK is undergoing significant changes to address the evolving role of pharmacists, who are increasingly involved in prescribing and complex clinical decision-making. The General Pharmaceutical Council's 2021 standards emphasize person-centered care, leadership, and clinical reasoning. From September 2026, newly qualified pharmacists in England will register as independent prescribers. This shift requires pharmacists to possess strong clinical knowledge and the ability to manage cognitive demands such as uncertainty, interruptions, and time pressure. Despite strong foundations in pharmacology and therapeutics, there is concern about whether pharmacy education adequately addresses the cognitive aspects of safe practice. A 2025 review highlighted frequent interruptions faced by pharmacists, impacting workload and performance. The World Health Organization and NHS England emphasize human factors in patient safety, suggesting a need for educational initiatives that address these cogniti...
Rapid Read Rapid Read
Government-Led Campaign Proposed to Reduce Dementia Risk in the UK

Government-Led Campaign Proposed to Reduce Dementia Risk in the UK

A new proposal suggests that a government-led campaign could significantly reduce the risk of dementia in the UK. Dementia, a leading cause of death, costs the economy £42 billion annually. Research indicates that nearly half of dementia cases could be prevented or delayed by addressing lifestyle-related risk factors such as physical inactivity, smoking, and poor diet. Despite this, a significant portion of the public is unaware that dementia risk can be reduced. Alzheimer's Research UK is advocating for a national campaign to educate the public on prevention strategies, emphasizing the role of the NHS in delivering this initiative.
Trendline Trendline
IQVIA's AI-Driven Solutions Boost Revenue Growth Amidst Strong Market Demand

IQVIA's AI-Driven Solutions Boost Revenue Growth Amidst Strong Market Demand

IQVIA's AI-Driven Solutions Boost Revenue Growth Amidst Strong Market Demand
Rapid Read Rapid Read
Colon Cancer Immunotherapy Breakthrough Keeps Patients Cancer-Free for Nearly Three Years

Colon Cancer Immunotherapy Breakthrough Keeps Patients Cancer-Free for Nearly Three Years

A UK-led clinical trial has demonstrated that a short course of immunotherapy before surgery can keep colorectal cancer patients cancer-free for nearly three years. The NEOPRISM-CRC study found that nine weeks of pembrolizumab treatment before surgery led to strong and lasting responses in patients with stage two or three colorectal cancer. The trial's success challenges the standard approach of surgery followed by chemotherapy, suggesting that starting with immunotherapy may offer longer-lasting protection against cancer recurrence.
Trendline Trendline
Cytospire Secures $83 Million for Innovative T-Cell Engager Platform Targeting Cancer

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform Targeting Cancer

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform Targeting Cancer
Trendline Trendline
Cytospire Secures $83 Million for Innovative T-Cell Engager Platform

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform
Trendline Trendline
Intelligent Copay Programs Transform Patient Access to Medications

Intelligent Copay Programs Transform Patient Access to Medications

Intelligent Copay Programs Transform Patient Access to Medications
Rapid Read Rapid Read
Amarox Recalls Sertraline Batch Due to Packaging Error Involving Antidepressants

Amarox Recalls Sertraline Batch Due to Packaging Error Involving Antidepressants

Amarox, a subsidiary of the Indian drugmaker Hetero Group, is recalling a batch of sertraline after mistakenly packaging it with a blister strip of another antidepressant, citalopram. The UK Medicines and Healthcare products Regulatory Agency (MHRA) announced the recall after a patient complaint revealed the error. The recall affects 100 mg film-coated tablets of sertraline, a selective serotonin reuptake inhibitor (SSRI). The error occurred during secondary packaging at the manufacturing facility. Healthcare professionals are advised to quarantine remaining stock and return it to suppliers. Pharmacists are instructed to contact patients who received the recalled product, especially those who received it in the past 28 days. The MHRA warns that concurrent exposure to two SSRIs may increase serotonergic effects, posing risks to patients, particularly those with pre-existing cardiac conditions or those taking other serotonergic medications.
Trendline Trendline
Survey Reveals Gaps in HR Professionals' Understanding of Employee Benefits

Survey Reveals Gaps in HR Professionals' Understanding of Employee Benefits

Survey Reveals Gaps in HR Professionals' Understanding of Employee Benefits
Trendline Trendline
Mubi Acquires Rights to Na Hong-Jin's 'Hope' for Multiple Territories

Mubi Acquires Rights to Na Hong-Jin's 'Hope' for Multiple Territories

Mubi Acquires Rights to Na Hong-Jin's 'Hope' for Multiple Territories
Trendline Trendline
Arnold Porter Strengthens Antitrust Practice with New Partner in London

Arnold Porter Strengthens Antitrust Practice with New Partner in London

Arnold Porter Strengthens Antitrust Practice with New Partner in London